European Antibody Congress


Discover. Develop. Get to market.

15-17 October | Congress Centre Basel


1-2-1 Meetings
Co-located events





Day 1 – Tuesday 15th October 2019
Opening Keynotes
Networking Break
Plenary roundtable session
Networking Lunch
Protein engineering Armed antibodies discovery Bispecifics development CMC and developability
Chaired by: Alain Beck, Senior Director, NBEs Analytical Chemistry, Pierre Fabre, Associate Editor, mAbs
mAbs Technology showcase
Networking Break
Protein engineering Bispecifics development CMC and developability mAbs Technology showcase
Offsite Networking Drinks



Day 2 – Wednesday 16th October 2019
Combination therapies
Protein engineering
Chaired by: Benjamí Oller-Salvia, Assistant Professor, IQS School of Engineering, Ramon Llull University
Armed antibodies discovery Bispecifics development
Chaired by: John Delaney, Executive Director of Research, Amgen
CMC and developability
Chaired by: Patrick Garidel, Head of Process, Purification and Pharma Development, Boehringer Ingelheim
Manufacture and bioprocessing
Networking Lunch
Protein engineering Bispecifics development CMC and developability
Networking Break
Bioanalysis and PK/PD
Poster presentation and networking drinks



Day 3 – Thursday 17th October 2019
Day 3 plenary session. World leading research
Networking Break
Analytics, screening and immune repertoire technologies
Chaired by: Christoph Merten, Group Leader, Microfluidics, European Molecular Biology Laboratory (EMBL)
In silico discovery and development for antibodies
Chaired by: Anke Steinmetz, Senior Researcher, Integrated Drug Discovery, Sanofi Aventis R&D
Nanobodies, peptides, novel modalities and non-antibody formats Regulation and investment Research hub
Chaired by: Andreas Laustsen, Associate Professor, Technical University of Denmark
Networking Lunch
Closing keynotes
Chaired by: Alain Beck, Senior Director, Biologics CMC and Developability, Pierre Fabre, Associate Editor, mAbs
Chair’s closing remarks
Alain Beck, Senior Director, Biologics CMC and Developability, Pierre Fabre, Associate Editor, mAbs
Closing remarks from Terrapinn
End of congress – see you in 2020!




Antibody-drug conjugates: Future directions in clinical and translational strategies

• Provide an overview of the current ADC landscape and challenges
• Discuss the clinical and translational strategies to improve the therapeutic index for ADC’s
• Envision the future landscape for ADC’s

Steve Coats , VP R&D , AstraZeneca Early Oncology

Modulating therapeutic window of antibody drug conjugates by protein engineering

• Engineering multiple properties of monoclonal antibodies to maximize the therapeutic window
• Properties such as conjugation location, antibody internalization, antibody affinity, drug and linker type, as well as use of dual payloads will be discussed

Pavel Strop , Senior Director, Protein Engineering , Bristol Myers Squibb

An overview of pre-clinical activity of T cell bispecific antibodies

• An overview of the pre-clinical activity of two "2:1" TCBs which are currently in clinical development, including combination studies in animal models

Marina Bacac , Head of Cancer Immunotherapy Department 2 (CIT-2) , Roche Innovation Center Zurich

CQA-driven characterisation program for antibodies

• Timeline and extent of CQA assessment for a typical IgG
• Translation of CQAs to characterization needs
• Realization of a complete characterization program to streamline the compilation of the final control strategy

Christoph Roesli , Senior Fellow, Global Drug Development , Novartis Pharma AG

Antibody discovery at GSK with a focus on Immunological and Immuno-oncology targets

• The progress with the isolation of antibodies for a number of projects in the immunology and immune-oncology disease areas using GSKs in-vitro and in-vivo antibody platforms
• Innovative antibody design and selection approaches will be discussed

Ruud De Wildt , Director, Head Of Antibody Discovery , GSK

The future of biologic therapeutics and their unique challenges

• Large molecule protein therapeutics have risen to play a significant role in disease modulation
• Bi-specific protein therapeutics are emerging as the next wave of protein therapeutics
• Bi-specific molecules pose unique challenges to current manufacturing processes

Dr John Delaney , Executive Director, Amgen Biologics Discovery , Amgen

The power of chemoselectivity: Protein-conjugates for intracellular targeting

• Site-selective conjugates of cyclic cell-penetrating peptides (cCPPs) to proteins enables their non-endosomal cellular uptake (transduction) in living cells
• Combining this delivery strategy with peptide tags and additional chemical modifications directs the protein cargo to specific intracellular compartments
• By using cCPP-conjugation cell-permeable nanobodies were generated, which showed transduction at low µM concentrations
• Live-cell microscopy and functional assays demonstrated the successful cellular delivery of functional biologically and therapeutically relevant proteins

Christian Hackenberger , Department Head Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) , Humboldt University Berlin



Sign Up for Event Updates


There are two parts to the Festival of Biologics: four conferences covering Antibodies, Immunotherapy, Biosimilars and Clinical Trials and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.